Bio Sequence

Is it sufficient to use only one encoding rule for the retrieval of antibody CDR sequences in FTO?

16 October 2023
2 min read

To reduce the risk of missing FTO sequences in antibody searches, it is insufficient to use only one encoding rule for CDR sequences. Antibody CDR sequences have multiple encoding rules, including the common ones such as Kabat, IMGT, Chothia, etc., and the CDR sequences under different encoding rules are not consistent. Therefore, to ensure the comprehensiveness of the FTO search and reduce the risk of omissions, at least two or more encoding rules should be selected. It is commonly suggested in this field that the CDR sequences under the Kabat, IMGT, and Chothia codes should be searched.

Here, it is recommended to use the Patsnap Bio Sequence Database for antibody sequence retrieval. This database supports the input of CDR sequences under five coding rules, which is convenient and greatly improves the work efficiency of the searchers.

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

What is Disease-Specific Survival (DSS) in Clinical Trials?
"What" Series
2 min read
What is Disease-Specific Survival (DSS) in Clinical Trials?
16 October 2023
Disease-Specific Survival (DSS) refers to deaths caused specifically by a particular disease.
Read →
Nature releases preclinical outcomes for ABBV-CLS-484, a PTPN2/N1 inhibitor in Cancer Immunotherapy
Latest Hotspot
4 min read
Nature releases preclinical outcomes for ABBV-CLS-484, a PTPN2/N1 inhibitor in Cancer Immunotherapy
16 October 2023
Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.
Read →
What is Milestone Survival in Clinical Trials?
"What" Series
2 min read
What is Milestone Survival in Clinical Trials?
16 October 2023
Milestone survival rate is defined as the survival probability at a given point in time.
Read →
Moderna Unveils Phase 1/2 Results for mRNA-1083
Latest Hotspot
3 min read
Moderna Unveils Phase 1/2 Results for mRNA-1083
16 October 2023
Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.